Insider transaction and option exercise
Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals INC (NASDAQ:LGND), sold 11,223 shares of common stock on March 4, 2026. The disposals generated approximately $2.76 million in proceeds, with trade prices spanning $198.7052 to $208.796 per share. The sales were carried out pursuant to a Rule 10b5-1 trading plan that Espinoza adopted on November 19, 2025.
On the same date, Espinoza exercised stock options to acquire 2,073 shares at exercise prices of $58.49 and $80.72, representing a combined cost of $131,608. After completing the sale and the option exercises, Espinoza directly owns 21,662 shares of Ligand Pharmaceuticals.
Market context and valuation note
The insider activity occurred as Ligand's shares trade close to their 52-week high of $212.49 and after a 76% total return over the past year. An InvestingPro analysis cited within company coverage indicates the stock currently appears overvalued relative to its Fair Value, with shares trading at a price-to-earnings ratio of 31.18.
Recent financial performance and analyst reactions
Ligand reported a strong fourth quarter for 2025, posting adjusted earnings per share of $2.02, above the analyst consensus of $1.49. Fourth-quarter revenue totaled $59.7 million, ahead of the $55.6 million estimate. For the full year, Ligand recorded revenue of $268 million, of which core revenue was $240 million, and reported a full-year adjusted EPS of $8.13.
Analyst moves followed the results. Oppenheimer raised its price target on Ligand to $277 from $275 and maintained an Outperform rating, citing the company's robust royalty revenue of $50.5 million for the fourth quarter. Stifel reiterated its Buy rating and kept a $230 price target, noting the company's strong financial performance.
What this means in plain terms
The public filings show a patterned insider sale executed under a pre-planned trading arrangement, coupled with an exercise of long-held options. These transactions occurred in the context of stronger-than-expected quarterly results and follow-through analyst support, while third-party analysis flags valuation metrics that may be above the company's assessed Fair Value.